Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.

Publication Type:

Journal Article


Journal of medical economics, Volume 17, Issue 1, p.32-42 (2014)


2014, April 2014, Center-Authored Paper, Institute for Cancer Outcomes Research and Evaluation (ICORE), Public Health Sciences Division


Evaluate the cost-effectiveness of primary vs secondary prophylaxis (PP vs SP) with pegfilgrastim to reduce the risk of febrile neutropenia (FN) in Non-Hodgkin's Lymphoma (NHL) patients receiving myelosuppressive chemotherapy from a US payer perspective.